莫沙必利联合雷贝拉唑钠治疗反流性食管炎的疗效和安全性研究

Study on the Efficacy and Safety of Mosapride Combined with Rabeprazole Sodium in the Treatment of Reflux Esophagitis

目的:分析莫沙必利联合雷贝拉唑钠治疗反流性食管炎(RE)的疗效和安全性。方法:选取2018年5月至2021年3月河南省直第三人民医院RE患者114例,按随机数字表法分为联合组(n=57)与单一组(n=57),单一组采用雷贝拉唑钠,联合组在单一组基础上加用莫沙必利。对比两组疗效、反流情况、内镜分级、胃肠激素[血管活性肠肽(VIP)、胃泌素(GAS)]、炎性因子[肿瘤坏死因子-α(TNF-α)、白细胞介素-6(IL-6)]、不良反应发生率。结果:联合组总有效率96.49%(55/57)较单一组84.21%(48/57)高(P<0.05);与单一组相比,治疗后联合组反流持续最长时间较短、反流持续时间≥5 min次数较少(P<0.05);联合组内镜分级优于单一组(P<0.05);治疗后,联合组VIP较单一组低,GAS较单一组高(P<0.05);与单一组相比,治疗后联合组TNF-α、IL-6较低(P<0.05);联合组不良反应发生率5.26%(3/57)与单一组8.77%(5/57)相比差异无统计学意义(P>0.05)。结论:莫沙必利联合雷贝拉唑钠治疗RE患者可调节胃肠激素和炎性因子表达,改善反流症状和胃镜分级,提高临床疗效,且安全性良好。

Objective:To analyze the efficacy and safety of mosapride combined with rabeprazole sodium in the treatment of reflux esophagitis(RE).Methods:A total of 114 RE patients in the Henan NO.3 Provincial People's Hospital from May 2018 to March 2021 were selected and divided into a combination group(n=57)and a single group(n=57)according to the random number table method.The single group was given rabeprazole sodium,and the combination group was given mosapride on the basis of the single group.The curative effect,reflux status,endoscopic grading,gastrointestinal hormones(VIP,GAS),inflammatory factors(TNF-α,IL-6),and incidence of adverse reactions were compared between the two groups.Results:The total effective rate of the combination group was 96.49%(55/57),which was higher than that of the single group[84.21%(48/57)](P<0.05).Compared with the single group,the longest duration of reflux in the combination group after treatment was shorter and the number of reflux duration≥5 min was less(P<0.05).The endoscopic grading of the combination group was better than that of the single group(P<0.05).After treatment,the VIP of the combination group was lower than that of the single group,and the GAS was higher than that of the single group(P<0.05).After treatment,the TNF-α、IL-6 of the combination group was lower than that of the single group(P<0.05).There was no significant difference in the incidence of adverse reactions between the combination group[5.26%(3/57)]and the single group[8.77%(5/57)](P>0.05).Conclusions:Mosapride combined with rabeprazole sodium can regulate the expression of gastrointestinal hormones and inflammatory factors in patients with RE,improve reflux symptoms and gastroscopic grading,improve clinical efficacy,and have good safety.